Neuropathology Department

1. European Regional Development Fund and the Republic of Cyprus through the Research and Innovation Foundation (Project: POST-DOC/0718/0113)

According to the Alzheimer Disease (AD) amyloid hypothesis, the deposition of prefibrillar and fibrillar alpha-beta peptide sets off pathogenic cascades of neuroinflammation and neurodegeneration that lead to synaptic and neuronal loss and cognitive decline. The complement cascade has been found to modulate the disease even though the mechanism of action is highly controversial. Animal experiments in the AD mouse model show that inhibition of the complement component C5a (a terminal product of complement activation) reduces amyloid and alleviates the pathology. Macrophages and neutrophils carry C5a receptors. In the mouse model for ATTR V30M neuropathy, C5a receptor inhibition exacerbates amyloid deposition while administration of the full C5a agonist significantly reduces amyloid deposition.

2. Cyprus Research Foundation Grant, Principal Investigator ‘A study of modifier genes on disease severity in Multiple sclerosis’ Support period: 2011-2013, 179,915 Euro

3. Cyprus Research Foundation Grant, Principal Investigator «A study of the role of complement C1Q in an animal model of Familial Amyloidotic neuropathy Type I». Support period: 1 April 2009-30 Sept 2011, 160,000 Euros

4. Cyprus Research Foundation Grant : «A study of modifier genes in Mitochondrial Encephalomyopathies», Support period  : 1 September  2005-  1 January 2008,   £ 56,200

5. Telethon Grant «Therapeutic trial of Melatonin and Trimetazidine in a Transgenic  Mouse Model of Familial ALS», 14 January 2004 – 15 January 2006, £ 36,200

6. Cyprus Research Foudation Grant: «Cyprus Study of Familial Amyloidotic neuropathy Type I», 16   December 2002 – 15 June 2005,  £ 49,700

7. MDA Grant  (USA),  «Neuromuscular diseases in Eastern Mediterranean countries»,  1 July  2002 – 30 June  2005,  $192,180.

8. MDA Grant  (USA)  “Neuromuscular diseases in Eastern  Mediterranean Countries”  Co-investigator , 1November 1994 – 31 October  1996,  US $ 204,400

9.  MDA Grant  (USA) “Clinical and genetic studies of Charcot-Marie-Tooth type II  and recessive forms”,  Co-investigator , 1 March 1996  – 30 June  1999, US $   201,150

10.  MDA (AFM, France) “Molecular genetics of Charcot- Marie-Tooth type II”, Co- investigator   1996, FF 180,000

11. MDA Grant  (USA) “Neuromuscular diseases in Eastern Mediterranean countries”, Co-investigator,  1 February 1997 – 30 June 1999,  US $ 158,000

12. MDA Grant (USA) “Neuromuscular diseases in eastern Mediterranean countries”, Co-investigator, 1 July 1999 – 30 June 2002,  US $ 135,000

13. MDA Grant  (USA)“Genetic studies in autosomal recessive hereditary motor  neuronopathy and autosomal recessive inclusion body myopathy”, Co-investigator,1July 1999 – 30 June  2002, US $ 180,000